Auswahl der wissenschaftlichen Literatur zum Thema „Drug-Polymer conjugates“
Geben Sie eine Quelle nach APA, MLA, Chicago, Harvard und anderen Zitierweisen an
Inhaltsverzeichnis
Machen Sie sich mit den Listen der aktuellen Artikel, Bücher, Dissertationen, Berichten und anderer wissenschaftlichen Quellen zum Thema "Drug-Polymer conjugates" bekannt.
Neben jedem Werk im Literaturverzeichnis ist die Option "Zur Bibliographie hinzufügen" verfügbar. Nutzen Sie sie, wird Ihre bibliographische Angabe des gewählten Werkes nach der nötigen Zitierweise (APA, MLA, Harvard, Chicago, Vancouver usw.) automatisch gestaltet.
Sie können auch den vollen Text der wissenschaftlichen Publikation im PDF-Format herunterladen und eine Online-Annotation der Arbeit lesen, wenn die relevanten Parameter in den Metadaten verfügbar sind.
Zeitschriftenartikel zum Thema "Drug-Polymer conjugates"
Libánská, Alena, Eva Randárová, Franck Lager, Gilles Renault, Daniel Scherman und Tomáš Etrych. „Polymer Nanomedicines with Ph-Sensitive Release of Dexamethasone for the Localized Treatment of Inflammation“. Pharmaceutics 12, Nr. 8 (25.07.2020): 700. http://dx.doi.org/10.3390/pharmaceutics12080700.
Der volle Inhalt der QuelleDuncan, Ruth. „Drug-polymer conjugates“. Anti-Cancer Drugs 3, Nr. 3 (Juni 1992): 175–210. http://dx.doi.org/10.1097/00001813-199206000-00001.
Der volle Inhalt der QuelleDuncan, R. „Designing polymer conjugates as lysosomotropic nanomedicines“. Biochemical Society Transactions 35, Nr. 1 (22.01.2007): 56–60. http://dx.doi.org/10.1042/bst0350056.
Der volle Inhalt der QuelleElvira, C., A. Gallardo, J. Roman und A. Cifuentes. „Covalent Polymer-Drug Conjugates“. Molecules 10, Nr. 1 (31.01.2005): 114–25. http://dx.doi.org/10.3390/10010114.
Der volle Inhalt der QuelleKončič, Marijana, Branka Zorc und Predrag Novak. „Macromolecular prodrugs. XIII. Hydrosoluble conjugates of 17β-estradiol and estradiol-17β-valerate with polyaspartamide polymer“. Acta Pharmaceutica 61, Nr. 4 (01.12.2011): 465–72. http://dx.doi.org/10.2478/v10007-011-0039-x.
Der volle Inhalt der QuelleKostková, H., L. Schindler, L. Kotrchová, M. Kovář, M. Šírová, L. Kostka und T. Etrych. „Star Polymer-Drug Conjugates with pH-Controlled Drug Release and Carrier Degradation“. Journal of Nanomaterials 2017 (2017): 1–10. http://dx.doi.org/10.1155/2017/8675435.
Der volle Inhalt der QuelleKumar, Sahil, Alka Sharma, Rajesh K. Singh, DN Prasad und TR Bhardwaj. „Synthesis and in vitro drug release studies on substituted polyphosphazene conjugates of lumefantrine.“ International Journal of Drug Delivery 9, Nr. 2 (06.10.2017): 36. http://dx.doi.org/10.5138/09750215.2133.
Der volle Inhalt der QuelleGrigoletto, Antonella, Gabriele Martinez, Daniela Gabbia, Tommaso Tedeschini, Michela Scaffidi, Sara De Martin und Gianfranco Pasut. „Folic Acid-Targeted Paclitaxel-Polymer Conjugates Exert Selective Cytotoxicity and Modulate Invasiveness of Colon Cancer Cells“. Pharmaceutics 13, Nr. 7 (23.06.2021): 929. http://dx.doi.org/10.3390/pharmaceutics13070929.
Der volle Inhalt der QuelleWadhwa, Saurabh, und Russell J. Mumper. „Polymer-Drug Conjugates for Anticancer Drug Delivery“. Critical Reviews in Therapeutic Drug Carrier Systems 32, Nr. 3 (2015): 215–45. http://dx.doi.org/10.1615/critrevtherdrugcarriersyst.2015010174.
Der volle Inhalt der QuelleBöhmová, Eliška, Robert Pola, Michal Pechar, Jozef Parnica, Daniela Machová, Olga Janoušková und Tomáš Etrych. „Polymer Cancerostatics Containing Cell-Penetrating Peptides: Internalization Efficacy Depends on Peptide Type and Spacer Length“. Pharmaceutics 12, Nr. 1 (10.01.2020): 59. http://dx.doi.org/10.3390/pharmaceutics12010059.
Der volle Inhalt der QuelleDissertationen zum Thema "Drug-Polymer conjugates"
Devenish, Sean. „Studies of natural product derivatives: targeted polymer drug conjugates“. Thesis, University of Canterbury. Chemistry, 2004. http://hdl.handle.net/10092/6661.
Der volle Inhalt der QuelleGilbert, Helena Rosalind Petra. „Bioresponsive polymer-protection conjugates as a unimolecular drug delivery system“. Thesis, Cardiff University, 2007. http://orca.cf.ac.uk/55685/.
Der volle Inhalt der QuelleChau, Ying. „Targeted drug delivery by novel polymer-drug conjugates containing linkers cleavable by disease-associated enzymes“. Thesis, Massachusetts Institute of Technology, 2005. http://hdl.handle.net/1721.1/32332.
Der volle Inhalt der QuelleIncludes bibliographical references.
We have conceptualized a new class of polymer-linker-drug conjugates to achieve targeted drug delivery for the systemic treatment of cancer and other inflammatory diseases. The physiochemical properties of the polymer allow the conjugate to circulate longer in the body by minimizing renal and hepatic clearance, thereby improving the pharmacokinetics of the attached drugs. Traditionally, linkers are degraded by acidity or by some ubiquitous intracellular enzymes. We incorporate linkers that are sensitive to a specific extracellular enzyme whose overexpression is co-localized with the diseased tissue. The drug molecules remain inactive when attached to the polymer, thus preventing normal tissues from harmful side effects. When the conjugate is transported to the diseased area where there is a high level of the target enzyme, the linkers are cleaved to release the drugs at the specific site. As an example, we designed and synthesized two generations of novel polymer-peptide-drug conjugates for the tumor-targeted delivery of chemotherapeutics. To allow for passive targeting and enhanced permeation and retention (EPR), dextran with a size greater than 6 nm was selected as the polymeric carrier. This biocompatible and biodegradable carrier was chemically modified to allow for conjugation with doxorubicin and methotrexate, two common chemotherapeutics with undesirable side effects.
(cont.) Since matrix-metalloproteinases (MMPs) are associated with a number of types of cancer and their functions are essential to disease progression, including degrading extracellular matrix, releasing angiogenic factors and activating growth factors, we explored the possibility of MMP-mediated drug release. The synthesis procedures combined solid phase and solution phase techniques to enable flexibility in the linker design and in the charge modification of the polymer. This scaleable and robust process produced new conjugates that demonstrated excellent stability under physiological conditions and optimized sensitivity to enzymatic cleavage by MMP-2 and MMP-9. The new conjugate, dextran-peptide-methotrexate, was assessed for its in vivo anti-tumor efficacy and systemic side effects. It was compared to free methotrexate and a similar conjugate, differing by an MMP-insensitive linker, at equivalent intraperitoneal dosages administered weekly. The MMP-sensitive conjugate resulted in effective inhibition of in vivo tumor growth in each of the two separate tumor models that overexpress MMP-2 and MMP-9 (HT-1080 and U- 87). In contrast, free methotrexate resulted in no significant tumor reduction in the same models. Neither free methotrexate nor the conjugate caused any tumor inhibition in mice bearing RT- 112, a slower-growing model which expresses significantly less MMP than HT-1080 and U-87 . The anti-proliferative effect of the drug contributed to the inhibition of tumor growth. Systemic side effects caused by the MMP-sensitive conjugates were tolerable.
(cont.) MMP-insensitive conjugates, though able to inhibit tumor growth, caused toxicity in the small intestine and bone marrow and the experiment was terminated after one injection. We conducted a biodistribution study in HT-1080 bearing mice to investigate the targeting mechanism of the new conjugate. Independent of the linker sequence, passive targeting was evidenced by the prolonged plasma circulation and higher tissue accumulations of the conjugates in comparison with free methotrexate. The ratios of drug accumulation at the tumor versus the major site of side effects (small intestine) for both conjugates were enhanced by the EPR effects. The difference in the drug accumulation at the tumor site was insignificant between conjugates with MMP-sensitive and MMP-insensitive linkers. We concluded that the tumor targeting effect of the dextran-peptide-methotrexate conjugate was dominantly due to passive targeting and EPR. The difference in the systemic side effects observed for the conjugates with different linkers was attributed to their varying susceptibility towards enzymes in normal tissues.
by Ying Chau.
Ph.D.
Sat, Nee Yee. „Factors that influence tumour targeting by the enhanced permeability and retention (EPR) effect“. Thesis, University College London (University of London), 1999. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.325320.
Der volle Inhalt der QuelleMina, James. „Hyaluronic acid based polymer drug conjugates for the treatment of rheumatoid arthritis“. Thesis, University of the West of Scotland, 2009. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.739391.
Der volle Inhalt der QuelleSingh, Jennifer. „Polymer-drug conjugates based on hyaluronic acid for the treatment of rheumatoid arthritis“. Thesis, University of the West of Scotland, 2004. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.415937.
Der volle Inhalt der QuelleJacobs, Jaco. „Poly(N-vinylpyrrolidone) - Poly(γ-benzyl-L-glutamate) conjugates“. Stellenbosch : Stellenbosch University, 2012. http://hdl.handle.net/10019.1/20369.
Der volle Inhalt der QuelleENGLISH ABSTRACT: The combination of natural and synthetic polymers allow for the synthesis of advanced hybrid copolymers. These hybrid copolymers have applications in biomedical areas, one such area being in drug delivery systems (DDS). In this study, a modular approach was used to prepare amphiphilic block copolymers with the ability to self-assemble into three dimensional structures. Reversible addition-fragmentation chain transfer (RAFT) was the synthetic tool used to mediate the polymerization of N-vinylpyrrolidone. RAFT is a versatile method to prepare polymers with control over molecular weight and dispersity. A xanthate chain transfer agent (CTA) was used to obtain the hydrophilic poly(N-vinylpyrrolidone) (PVP) block. An aldehyde functionality could be introduced due to the lability of the xanthate moiety, the procedure of which was effectively optimized to produce quantitative conversion. A dixanthate CTA was synthesized to produce a PVP chain which after the modification reaction, resulted in a α,ω-telechelic polymer. A polypeptide was synthesized via the ring-opening polymerization of Ncarboxyanhydrides (ROP NCA). The living and controllable ROP of NCAs is a method which results in polypeptides, but without a well-defined amino acid order. Poly(γ- benzyl-L-glutamate) (PBLG) was synthesized with a narrow dispersity (Đ = 1.10 – 1.15) using conditions that promote the retention of a terminal primary amine. A protected cysteine functionality was introduced via the terminal amine PBLG chain-end, using peptide synthesis techniques. This resulted in the conjugation of the aldehyde functional PVP and the cysteine terminal PBLG using a covalent, non-reducible thiazolidine linkage. The deprotection of the cysteine, more specifically the deprotection of the thiol was a non-trivial procedure. The thiol protecting acetamidomethyl (Acm) group could not be cleaved using traditional methods, but instead a modified procedure was developed to effectively remove the Acm group while inhibiting hydrolysis of the benzyl esters. It was determined that the conjugation reaction could effectively proceed in N,Ndimethylformamide (DMF) at a slightly elevated temperature and so continued to prepare the amphiphilic hybrid block copolymers, PVP-b-PBLG. A structurally different PBLG chain, namely PBLG-b-Cys was conjugated to the ω-aldehyde PVP and the conjugation efficiency was compared to our PBLG-Cys block. In the case of PBLG-b- Cys the in situ deprotection and conjugation as well as a two-step deprotection and conjugation reaction with PVP resulted in very low conjugation efficiency. The cysteine end-functional PBLG resulted in near quantitative conjugation with PVP. The critical micelle concentration (CMC) for PVP90-b-PBLG54 was determined to be 6 μg/mL, using fluorescence spectroscopy. Particle sizes were determined with TEM and DLS and found to range from 25 nm to 120 nm depending on the polymer block lengths as well as hydrophobic/hydrophilic block length ratios. Furthermore, when the micelles were subjected to an increased acidic environment, the labile benzyl ester bonds were hydrolyzed. This was observed with TEM where the particle sizes increased 10-fold to form vesicular structures. Hydrolysis was further confirmed with ATR-FTIR and 1H-NMR spectroscopy. Cytotoxicity tests confirmed that the copolymer micelles had good cell compatibility at high concentrations such as 0.9 mg/mL. Investigation into drug loading using a pyrene probe confirmed the viability of using PVP-b-PBLG as a responsive DDS.
AFRIKAANSE OPSOMMING: Die kombinasie van natuurlike en sintetiese polimere maak dit moontlik vir die sintese van gevorderde hibried kopolimere. Hierdie kopolimere het aanwending in biomediese gebiede, een so 'n gebied is in medisinale vervoer sisteme (MVS). 'n Modulêre benadering is in hierdie studie gebruik om amfifiliese blok kopolimere te berei. Omkeerbare addisie-fragmentasie kettingoordrag (OAFO) is gebruik as die sintetiese tegniek vir die polimerisasie van N-vinielpirolidoon (NVP). OAFO is 'n veelsydige metode om polimere te berei met beheer oor molekulêre gewig en dispersiteit (Đ). 'n Xantaat kettingoordrag agent (KOA) is gebruik om die hidrofiliese poli(N-vinielpirolidoon) (PVP) blok te sintetiseer. ‘n Aldehied endgroep was deur die terminale xantaat funksionaliteit berei, ‘n proses wat geoptimiseer is tot kwantitatiewe omsetting. 'n Di-xantaat KOA is gesintetiseer om, na modifikasie, 'n α, ω-telecheliese polimeer te produseer. Die polipeptied was gesintetiseer deur middel van ’n ringopening polimerisasie van Nkarboksianhidriede (ROP NKA). Die lewende en beheerbare ROP van NKAe is 'n metode wat lei tot polipeptiede sonder ’n gedefinieerde aminosuur volgorde. Poli(γ- benzyl-L-glutamaat) met 'n lae dispersiteit (Đ = 1.10 – 1.15), is gesintetiseer deur gebruik te maak van kondisies wat die behoud van 'n terminale primêre amien bevorder. 'n Beskermde sistien-funksionaliteit is ingebou via die terminale amien met behulp van peptiedsintese tegnieke. Die tiol beskerming van die asetamidometiel (Asm) groep kon nie gekleef word deur gebruik te maak van tradisionele metodes nie, maar ‘n nuwe proses is ontwikkel om die Asm groep te kleef sowel as om die hidrolise van die bensiel esters te inhibeer. Die koppelings reaksie het effektief verloop in DMF by 'n effens verhoogde temperatuur en sodoende is die amfifiliese hibried blok-kopolimere, PVP-b-PBLG berei. Twee verskillende PBLG kettings is gekoppel aan die ω-aldehied PVP en die koppeling doeltreffendheid is vergelyk. Daar is bevind dat net die sistien end-funksionele PBLG tot kwantitatiewe konjugasie kon lei. Die kritiese misel konsentrasie is bepaal vir PVP90-b-PBLG54 as 6 μg/mL met behulp van fluoressensie spektroskopie. Die deeltjie-groottes is bepaal met TEM en DLS en wissel van 25 nm tot 120 nm, afhangende van die polimeer bloklengtes sowel as hidrofobiese / hidrofiliese blok lengte verhoudings. Die miselle is blootgestel aan 'n verhoogde suur omgewing, wat tot die hidrolise van die bensiel ester groepe gelei het. TEM het getoon dat die deeltjie-groottes met 10-voud vergroot het tot vesikulêre strukture. Hidrolise is verder bevestig met ATR-FTIR en 1H-KMR spektroskopie. Sitotoksiese toetse het bevestig dat die miselle geen of min toksisiteit toon teenoor eukariotiese selle nie, selfs teen 'n hoë konsentrasies soos 0.9 mg/ml. Die medisinale behoud vermoë is met behulp van pireen bevestig en dus ook die potensiaal van PVP-b-PBLG as ‘n moontlike MVS.
Heinrich, Anne-Kathrin [Verfasser]. „Overcoming drug resistance by stimulus-sensitive drug delivery systems : a preclinical characterization of polymer-drug conjugates for the treatment of multi-drug resistant cancer / Anne-Kathrin Heinrich“. Halle, 2017. http://d-nb.info/1144955262/34.
Der volle Inhalt der QuelleKrishnan, Vinu. „Design and Synthesis of Nanoparticle “PAINT-BRUSH” Like Multi-Hydroxyl Capped Poly(Ethylene Glycol) Conjugates for Cancer Nanotherapy“. Akron, OH : University of Akron, 2008. http://rave.ohiolink.edu/etdc/view?acc%5Fnum=akron1217677351.
Der volle Inhalt der Quelle"August, 2008." Title from electronic thesis title page (viewed 12/9/2009) Advisor, Stephanie T. Lopina; Committee members, Amy Milsted, Daniel B. Sheffer, Daniel Ely; Department Chair, Daniel B. Sheffer; Dean of the College, George K. Haritos; Dean of the Graduate School, George R. Newkome. Includes bibliographical references.
Park, Jongryul. „Poly(2-oxazoline) architectures for drug delivery systems“. Thesis, Queensland University of Technology, 2021. https://eprints.qut.edu.au/211439/1/Jongryul_Park_Thesis.pdf.
Der volle Inhalt der QuelleBücher zum Thema "Drug-Polymer conjugates"
Ronit, Satchi-Fainaro, und Duncan R, Hrsg. Polymer therapeutics II: Polymers as drugs, conjugates, and gene delivery systems. Berlin: Springer, 2006.
Den vollen Inhalt der Quelle findenWang, Chun, und Youqing Shen. Polymer-Drug Conjugates. Springer London, Limited, 2020.
Den vollen Inhalt der Quelle findenChopra, Neetu, Jitender Madan, Ashish Baldi und Monika Chaudhary. Polymer-Drug Conjugates: Linker Chemistry, Protocols and Applications. Elsevier Science & Technology, 2023.
Den vollen Inhalt der Quelle findenChopra, Neetu, Jitender Madan, Ashish Baldi und Monika Chaudhary. Polymer-Drug Conjugates: Linker Chemistry, Protocols and Applications. Elsevier Science & Technology Books, 2023.
Den vollen Inhalt der Quelle finden(Editor), Ronit Satchi-Fainaro, und Ruth Duncan (Editor), Hrsg. Polymer Therapeutics I: Polymers as Drugs, Conjugates and Gene Delivery Systems (Advances in Polymer Science). Springer, 2006.
Den vollen Inhalt der Quelle findenDuncan, Ruth, und Ronit Satchi-Fainaro. Polymer Therapeutics I: Polymers as Drugs, Conjugates and Gene Delivery Systems. Springer, 2010.
Den vollen Inhalt der Quelle findenDuncan, Ruth, und Ronit Satchi-Fainaro. Polymer Therapeutics II: Polymers as Drugs, Conjugates and Gene Delivery Sytems. Springer, 2010.
Den vollen Inhalt der Quelle finden(Editor), Ronit Satchi-Fainaro, und Ruth Duncan (Editor), Hrsg. Polymer Therapeutics II: Polymers as Drugs, Conjugates and Gene Delivery Sytems (Advances in Polymer Science) (Advances in Polymer Science). Springer, 2006.
Den vollen Inhalt der Quelle findenBuchteile zum Thema "Drug-Polymer conjugates"
Fante, Cristina, und Francesca Greco. „Polymer-Drug Conjugates“. In Engineering Polymer Systems for Improved Drug Delivery, 55–83. Hoboken, NJ, USA: John Wiley & Sons, Inc., 2014. http://dx.doi.org/10.1002/9781118747896.ch3.
Der volle Inhalt der QuelleFante, Cristina, und Francesca Greco. „Polymer-Drug Conjugates“. In Fundamentals of Pharmaceutical Nanoscience, 159–82. New York, NY: Springer New York, 2013. http://dx.doi.org/10.1007/978-1-4614-9164-4_7.
Der volle Inhalt der QuelleKopeček, Jindřich, und Pavla Kopečková. „Design of Polymer-Drug Conjugates“. In Drug Delivery in Oncology, 483–512. Weinheim, Germany: Wiley-VCH Verlag GmbH & Co. KGaA, 2011. http://dx.doi.org/10.1002/9783527634057.ch17.
Der volle Inhalt der QuelleDuncan, Ruth. „Polymer-Drug Conjugates: Targeting Cancer“. In Biomedical Aspects of Drug Targeting, 193–209. Boston, MA: Springer US, 2002. http://dx.doi.org/10.1007/978-1-4757-4627-3_10.
Der volle Inhalt der QuelleMohanty, Anjan Kumar, Fahima Dilnawaz, Guru Prasad Mohanta und Sanjeeb Kumar Sahoo. „Polymer–Drug Conjugates for Targeted Drug Delivery“. In Advances in Delivery Science and Technology, 389–407. Cham: Springer International Publishing, 2014. http://dx.doi.org/10.1007/978-3-319-11355-5_12.
Der volle Inhalt der QuelleSingh, Sauraj, Ruchir Priyadarshi, Bijender Kumar, Saleheen Bano, Farha Deeba, Anurag Kulshreshtha und Yuvraj Singh Negi. „Polymer–Drug Conjugates as Drug Delivery Systems“. In Applications of Encapsulation and Controlled Release, 61–75. Boca Raton : CRC Press, Taylor & Francis Group, 2019.: CRC Press, 2019. http://dx.doi.org/10.1201/9780429299520-4.
Der volle Inhalt der QuelleAbu Ajaj, Khalid, und Felix Kratz. „Clinical Experience with Drug-Polymer Conjugates“. In Drug Delivery in Oncology, 839–84. Weinheim, Germany: Wiley-VCH Verlag GmbH & Co. KGaA, 2011. http://dx.doi.org/10.1002/9783527634057.ch26.
Der volle Inhalt der QuelleFrancis, Arul Prakash, und A. Jayakrishnan. „Chapter 11. Polymer–Drug Conjugates for Treating Local and Systemic Fungal Infections“. In Biomaterials Science Series, 303–24. Cambridge: Royal Society of Chemistry, 2019. http://dx.doi.org/10.1039/9781788012638-00303.
Der volle Inhalt der QuelleSwami, Rajan, Dinesh Kumar, Wahid Khan, Ramakrishna Sistla und Nalini Shastri. „Polymer–Drug Conjugate in Focal Drug Delivery“. In Advances in Delivery Science and Technology, 117–47. Boston, MA: Springer US, 2013. http://dx.doi.org/10.1007/978-1-4614-9434-8_5.
Der volle Inhalt der Quellepun, Suzie H., und Allan S. Hoffman. „Polymer–Drug Conjugates“. In Biomaterials Science, 1036–39. Elsevier, 2013. http://dx.doi.org/10.1016/b978-0-08-087780-8.00092-9.
Der volle Inhalt der QuelleKonferenzberichte zum Thema "Drug-Polymer conjugates"
Yurkovetskiy, Alex, Natalya Bodyak, Mao Yin, Joshua Thomas, Patrick Conlon, Cheri Stevenson, Alex Uttard et al. „Abstract 4331: Advantages of polyacetal polymer-based antibody drug conjugates employing cysteine bioconjugation.“ In Proceedings: AACR 104th Annual Meeting 2013; Apr 6-10, 2013; Washington, DC. American Association for Cancer Research, 2013. http://dx.doi.org/10.1158/1538-7445.am2013-4331.
Der volle Inhalt der QuelleFang, Yang, und Xiaobo Tan. „Design and Modeling of a Petal-Shape, Conjugated Polymer-Actuated Micropump“. In ASME 2008 Dynamic Systems and Control Conference. ASMEDC, 2008. http://dx.doi.org/10.1115/dscc2008-2278.
Der volle Inhalt der QuelleLam, Robert, Xueqing Zhang, Mark Chen und Dean Ho. „Functional Nanodiamond Internalization Mechanisms and Kinetics“. In ASME 2010 First Global Congress on NanoEngineering for Medicine and Biology. ASMEDC, 2010. http://dx.doi.org/10.1115/nemb2010-13339.
Der volle Inhalt der QuelleThomas, Joshua, Alex Yurkovetskiy, Natalya Bodyak, Mao Yin, Patrick Conlon, Cheri Stevenson, Alex Uttard et al. „Abstract C238: Polyacetal polymer-based anti-HER2 antibody-drug conjugate employing cysteine bioconjugation through thioether linkage allows a high drug loading of dolastatin-derived payload with excellent pharmacokinetics and potent anti-tumor activity.“ In Abstracts: AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics--Oct 19-23, 2013; Boston, MA. American Association for Cancer Research, 2013. http://dx.doi.org/10.1158/1535-7163.targ-13-c238.
Der volle Inhalt der QuelleBerichte der Organisationen zum Thema "Drug-Polymer conjugates"
Nan, Anjan. Targetable Polymer-Antiangiogenic Drug Conjugates for Systemic Breast Cancer Therapy. Fort Belvoir, VA: Defense Technical Information Center, September 2006. http://dx.doi.org/10.21236/ada462903.
Der volle Inhalt der QuelleLi, Chun. Radiation-Induced Chemosensitization: Potentiation of Antitumor Activity of Polymer-Drug Conjugates. Fort Belvoir, VA: Defense Technical Information Center, April 2002. http://dx.doi.org/10.21236/ada406209.
Der volle Inhalt der QuelleLi, Chun. Radiation Induced Chemosensitization: Potentiation of Antitumor Activity of Polymer-Drug Conjugates. Fort Belvoir, VA: Defense Technical Information Center, April 2003. http://dx.doi.org/10.21236/ada415707.
Der volle Inhalt der Quelle